Key Points Positive adjusted EBITDA could mark an important turnaround milestone. Sustained revenue growth could strengthen Canopy’s investment case. Free cash flow remains a major concern for investors. 10 stocks we like better than Canopy Growth › Canopy Growth (NASDAQ: CGC) is getting closer to something marijuana investors have been waiting years to see: positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). The Canada-based cannabis company recently reported Q1 fiscal 2027 net revenue of about $57.4 million, up 13% year over year, with growth across every major business. Cannabis revenue increased 14%, and growth wasn't limited to one market. Canadian medical cannabis revenue jumped 22% to about $18.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.